Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT04616131 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT04616131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04616131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy
Lead sponsor
Northwestern University
Phase
Observational
Overall status
Recruiting
Start date
October 1, 2020
Completion date
October 1, 2029
Enrollment
500 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer